Hunter Greene's Second Tommy John Surgery Ends Reds' Ace Era

Hunter Greene underwent Tommy John surgery on Wednesday to repair a damaged ulnar collateral ligament in his right elbow, marking the second time the Reds' ace has had the procedure performed. The surgery terminates his 2026 season and will sideline him through most or all of 2027. Greene, the second overall pick in 2017, reported soreness during a bullpen session on August 4 and underwent imaging the following day before seeking a second opinion from Dr. Neal ElAttrache in Los Angeles on August 6. Both surgeons determined that opening the elbow would reveal the full extent of the damage—a call that proved prescient.

The injury chain reveals a cascading problem that Cincinnati failed to arrest. Greene had arthroscopic surgery on March 11 to remove bone chips from the same elbow, a procedure typically indicative of ongoing inflammatory stress. Reds president of baseball operations Nick Krall stated that Greene reported soreness on and off for weeks following the March procedure but "wasn't something he brought to anyone's attention because he thought it was just, 'Hey, you're coming off the bone chip surgery. You're just going to push through it.'" That decision—Greene's own choice to pitch through post-surgical soreness—compressed what might have been a manageable recovery into a full ligament failure. For a 27-year-old who has landed on the injured list in all five of his major league seasons, this represents organizational failure in injury surveillance, not just bad luck.

Greene's track record, when available, was elite. His 2024 season—169 strikeouts over 150 1/3 innings with a sub-3.00 ERA and his lone All-Star selection—demonstrated ace-caliber production. Last season he posted a 2.76 ERA across 19 starts despite two separate IL stints. But the durability math is now untenable. Two Tommy John surgeries by age 27, compounded by a string of soft-tissue injuries (the 2025 right groin strain, the March 2026 bone chips), establish a pattern that recovery from this procedure is unlikely to reverse. The typical Tommy John timeline runs 12-18 months for a pitcher, placing Greene's realistic return in early 2028 at the earliest—if it happens at all.

For Cincinnati's betting profile, this erases a significant strikeout anchor from their rotation. Greene's 169 K's in 2024 anchored prop scenarios around Reds pitcher strikeout totals and bullpen usage; his absence forces reliance on younger, less predictable arms. The team's pitching staff will absorb additional inning volume from replacement starters, which typically correlates with higher walk rates and more bullpen deployment. Over/unders on Reds team totals should shift downward as the offense loses Greene's presence in high-leverage starts where his 1-2 punch with fellow ace Luis Castillo would suppress opposing scoring. Fade Reds team totals in games formerly penciled for Greene starts, particularly in matchups where the replacement starter carries a sub-140 ERA+. This is a durable angle because it's structural—Greene's absence is permanent through 2027—not a single-game variance.

The organizational implications are severe. A franchise that built around Greene and Castillo now faces a window collapse. Castillo alone cannot sustain a contender in the NL Central, and the financial commitment to Greene's contract (a five-year, $84 million deal signed in 2022) becomes a sunk cost with no remaining upside. Cincinnati's front office gambled on durability and lost.